A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Phase 1/2 Recruiting
132 enrolled
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Phase 1/2 Recruiting
146 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Phase 1/2 Recruiting
96 enrolled
CERTIS1
Phase 1/2 Recruiting
695 enrolled
MK-9999-01A
Phase 1/2 Recruiting
90 enrolled
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
Phase 1/2 Recruiting
70 enrolled
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Phase 1/2 Recruiting
66 enrolled
DURABLE
Phase 1/2 Recruiting
56 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Phase 1/2 Recruiting
42 enrolled
ADORATION
Phase 1/2 Recruiting
46 enrolled
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Phase 1/2 Recruiting
27 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/2 Recruiting
104 enrolled
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Phase 1/2 Recruiting
45 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/2 Recruiting
63 enrolled
NAVIG-1
Phase 1/2 Recruiting
35 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
GLOW-FISH
Phase 1/2 Recruiting
22 enrolled
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Phase 1/2 Recruiting
46 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
SPEARHEAD-3 Pediatric Study
Phase 1/2 Recruiting
20 enrolled
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/2 Recruiting
31 enrolled
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study.
Phase 1/2 Recruiting
125 enrolled
ELECTRA
Phase 1/2 Recruiting
73 enrolled
5G-PEARL
Phase 1/2 Recruiting
64 enrolled
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Phase 1/2 Recruiting
191 enrolled
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Phase 1/2 Recruiting
90 enrolled
5G-RUBY
Phase 1/2 Recruiting
182 enrolled
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Phase 1/2 Recruiting
30 enrolled
SOLARA
Phase 1/2 Recruiting
41 enrolled
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Phase 1/2 Recruiting
30 enrolled
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Phase 1/2 Recruiting
6 enrolled
Clinical Study of Oncolytic Virus in Glioblastoma
Phase 1/2 Recruiting
20 enrolled
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Phase 1/2 Recruiting
20 enrolled
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
Phase 1/2 Recruiting
42 enrolled
DETERMINE
Phase 1/2 Recruiting
33 enrolled
WAYWIN103
Phase 1/2 Recruiting
48 enrolled
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Phase 1/2 Recruiting
260 enrolled
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/2 Recruiting
75 enrolled
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
Phase 1/2 Recruiting
12 enrolled
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Phase 1/2 Recruiting
57 enrolled
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Phase 1/2 Recruiting
65 enrolled
RABBIT
Phase 1/2 Recruiting
30 enrolled
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Phase 1/2 Recruiting
50 enrolled
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Phase 1/2 Recruiting
50 enrolled
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 Recruiting
3 enrolled